Sanofi Names Belén Garijo as Chief Executive After Board Decides Not to Renew Paul Hudson
Sanofi said it will replace CEO Paul Hudson with Belén Garijo after choosing not to renew Hudson's mandate. The decision comes as the company seeks new growth drivers following mixed trial results and prepares for patent losses on its asthma drug Dupixent in the early 2030s. Hudson will step down on February 17, an interim CEO will lead through the…